Bailey Blankenship
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (59.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Sanofi at 56.6% of the total. 2025 is the largest year on record at $33,285, more than ten times the $136 reported in 2022. Among family clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 84 payments — averaging $502.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$24K
- Regeneron Healthcare Solutions, Inc.$12K
- Enterra Medical, Inc.$6K
- Ardelyx, Inc.$123
- Evoke Pharma, Inc.$118
- Gilead$14
What the payments were for
- Consulting fees$7,57218%
- Speaking & faculty fees$25,03759%
- Travel & lodging$7,13117%
- Food & beverage$2,4936%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 35 | $23,910 |
| Regeneron Healthcare Solutions, Inc. | 38 | $12,114 |
| Enterra Medical, Inc. | 8 | $5,955 |
| Ardelyx, Inc. | 1 | $123 |
| Evoke Pharma, Inc. | 1 | $118 |
| Gilead | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$42,233 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 22 | $67,241 |
| LinzessLinaclotide | 65 | $51,093 |
| Dexlansoprazole DrDexlansoprazole | 12 | $3,527 |
| Lubiprostone | 14 | $3,415 |
| Esomeprazole Magnesium | 20 | $2,186 |
| Omeprazole | 62 | $1,337 |
| Pantoprazole Sodium | 50 | $730 |
| Famotidine | 35 | $496 |
| Ondansetron OdtOndansetron | 18 | $347 |
| Dicyclomine Hcl | 11 | $301 |
| Mirtazapine | 16 | $244 |
| Amitriptyline Hcl | 29 | $226 |
| Ondansetron Hcl | 11 | $140 |
Paid to pharmacies, not to this prescriber.
Other family in Tampa
- Lewis HarringtonTampa$954K
- Marie Labadie-DegennaroTampa$66K
- Polly BittleTampa$63K
- Katharine WilliamsTampa$47K
- Candace DeberryTampa$46K
- Rasheeta ChandlerTampa$37K
- Rosaly TorresTampa$28K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.